UnknownPhase 2NCT03239015
Efficacy and Safety of Precision Therapy in Refractory Tumor
Studying Rare neoplastic disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Baodong Qin
- Principal Investigator
- Yuan-Sheng Zang, MD.PHDShanghai Changzheng Hospital
- Intervention
- Gefitinib(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2017 – 2023
Study locations (1)
- Shanghai Changzheng Hospital, Shanghai, Shanghai Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03239015 on ClinicalTrials.govOther trials for Rare neoplastic disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07147465Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology PatientsAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT04423185PLATFORM Study of Precision Medicine for Rare TumorsCancer Institute and Hospital, Chinese Academy of Medical Sciences